ASCO 2007: plenary top 5.
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001557:Benzenesulfonates / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000628:therapy; D002292:Carcinoma, Renal Cell / Q000628:therapy; D018288:Carcinoma, Small Cell / Q000628:therapy; D015179:Colorectal Neoplasms / Q000628:therapy; D006801:Humans; D007680:Kidney Neoplasms / Q000628:therapy; D015473:Leukemia, Promyelocytic, Acute / Q000628:therapy; D008113:Liver Neoplasms / Q000628:therapy; D008175:Lung Neoplasms / Q000473:pathology / Q000628:therapy; D008495:Medical Oncology; D009369:Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011725:Pyridines / Q000627:therapeutic use; D012955:Societies, Medical; D000077157:Sorafenib; D014481:United States
D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib